Remove Clinical Pharmacology Remove Information Remove Licensing
article thumbnail

Vamorolone

New Drug Approvals

“Agamree Product information” Union Register of medicinal products. “Population Pharmacokinetics of Vamorolone (VBP15) in Healthy Men and Boys With Duchenne Muscular Dystrophy” Journal of Clinical Pharmacology. Retrieved 27 December 2023. Reproduction is authorized provided the source is acknowledged.

FDA 62
article thumbnail

Landiolol

New Drug Approvals

“Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias” Clinical Pharmacology and Therapeutics. National Center for Biotechnology Information (NCBI). . ^ Atarashi H, Kuruma A, Yashima M, Saitoh H, Ino T, Endoh Y, et al. August 2000). 68 (2): 14350.

FDA 62
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Why Proactive AME Studies are Critical to Accelerating Your Approval Journey

Conversations in Drug Development Trends

The on-site cGMP Phase 1 pharmacy must have radiolabel drug preparation experience A clinical pharmacology unit (CPU) must be licensed and experienced in handling radioactive investigational drugs in order to complete your AME study.

article thumbnail

Trends & Insights: Spotlight Winter Edition

DrugBank

Read the paper Jörn Lötsch Biomedical scientist at the Goethe - University Frankfurt am Main, Germany Research Focus: Knowledge discovery by combining artificial and human intelligence for information reduction of biomedical data with a focus on data science, pain, and clinical pharmacology.

article thumbnail

Eplontersen

New Drug Approvals

“Population pharmacokinetic/pharmacodynamic modelling of eplontersen, an antisense oligonucleotide in development for transthyretin amyloidosis” British Journal of Clinical Pharmacology. “International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 85” WHO Drug Information.

article thumbnail

TLC Provides Corporate Update at Investor Conference – Dec 18, 2020

The Pharma Data

With experiences attained in licensing and business development functions from Amgen, Baxter and Johnson & Johnson, Mr. Bliss introduced himself in Mandarin Chinese. The Phase I clinical trial is ongoing in Taiwan in Australia, with results expected in 2021. SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Dec. Source link.

article thumbnail

Analysis Life Sciences Thank You What We Expect the FDA to do in July and August 2024

Agency IQ

FDA Regulations and guidance under OIRA review as of July The White House’s Office of Information and Regulatory Affairs (OIRA) is the regulator of regulators, tasked with ensuring that all federal policies and regulations adhere to laws, existing regulations, federal policies and the wishes of the President.

FDA 40